Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 99 of 99 matching drugs for GPI — including drugs targeting any of its 27 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
disulfiram, copper, alkylating agents GPI Direct 1
adagrasib KRAS SSL via KRAS yes 2
sotorasib KRAS SSL via KRAS yes 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LCK SSL via LCK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAP2K2 SSL via MAP2K2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3CG SSL via PIK3CG 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SRC SSL via SRC 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2K2 SSL via MAP2K2 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LCK SSL via LCK 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SRC SSL via SRC 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib MAP2K2 SSL via MAP2K2 2
cft1946, trametinib, cetuximab MAP2K2 SSL via MAP2K2 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib TYK2 SSL via TYK2 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib MAP2K2 SSL via MAP2K2 2
nintedanib LCK SSL via LCK 2
nintedanib SRC SSL via SRC 2
nintedanib, pembrolizumab LCK SSL via LCK 2
nintedanib, pembrolizumab SRC SSL via SRC 2
selumetinib, medi4736, tremelimumab MAP2K2 SSL via MAP2K2 2
adjuvant therapy, temozolomide, valproic acid, radiation therapy CDKN1A SSL via CDKN1A 1
adriamycin, cyclophosphamide, vindesine, valproic acid CDKN1A SSL via CDKN1A 1
afatinib, dasatinib, palbociclib, everolimus, olaparib LCK SSL via LCK 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SRC SSL via SRC 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib MAP2K2 SSL via MAP2K2 1
aminolevulinic acid ALAD SSL via ALAD 1
aminolevulinic acid, surgical resection ALAD SSL via ALAD 1
arsenic trioxide CDKN1A SSL via CDKN1A 1
arsenic trioxide, radiation therapy CDKN1A SSL via CDKN1A 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy CDKN1A SSL via CDKN1A 1
atezolizumab, tivozanib PTK6 SSL via PTK6 1
bevacizumab, dasatinib, placebo LCK SSL via LCK 1
bevacizumab, dasatinib, placebo SRC SSL via SRC 1
binimetinib MAP2K2 SSL via MAP2K2 yes 1
binimetinib, hydroxychloroquine MAP2K2 SSL via MAP2K2 1
biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging PIK3CG SSL via PIK3CG 1
biopsy, biospecimen collection, copanlisib, radiologic examination PIK3CG SSL via PIK3CG 1
bosutinib MAP2K2 SSL via MAP2K2 1
bosutinib SRC SSL via SRC yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab LCK SSL via LCK 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SRC SSL via SRC 1
dabrafenib, trametinib MAP2K2 SSL via MAP2K2 1
dabrafenib, trametinib, carboplatin, vincristine MAP2K2 SSL via MAP2K2 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride LCK SSL via LCK 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride SRC SSL via SRC 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method LCK SSL via LCK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method SRC SSL via SRC 1
dasatinib, laboratory biomarker analysis, physiologic testing LCK SSL via LCK 1
dasatinib, laboratory biomarker analysis, physiologic testing SRC SSL via SRC 1
dasatinib, mfolfox6 LCK SSL via LCK 1
dasatinib, mfolfox6 SRC SSL via SRC 1
dasatinib, pharmacological study LCK SSL via LCK 1
dasatinib, pharmacological study SRC SSL via SRC 1
dasatinib, temozolomide, placebo, radiation therapy LCK SSL via LCK 1
dasatinib, temozolomide, placebo, radiation therapy SRC SSL via SRC 1
erlotinib hydrochloride, selumetinib, laboratory biomarker analysis MAP2K2 SSL via MAP2K2 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim MAP2K2 SSL via MAP2K2 1
gsk2256098, trametinib MAP2K2 SSL via MAP2K2 1
lmb-100, tofacitinib, mesothelin expression TYK2 SSL via TYK2 1
ponatinib LCK SSL via LCK 1
ponatinib SRC SSL via SRC 1
porfimer sodium LDLR SSL via LDLR 1
porfimer sodium, adjuvant therapy, conventional surgery LDLR SSL via LDLR 1
porfimer sodium, endoscopic ultrasonography, photodynamic therapy, gemcitabine hydrochloride LDLR SSL via LDLR 1
ruxolitinib TYK2 SSL via TYK2 1
ruxolitinib, erlotinib TYK2 SSL via TYK2 1
ruxolitinib, radiation, temozolomide TYK2 SSL via TYK2 1
selumetinib MAP2K2 SSL via MAP2K2 yes 1
sirolimus, vandetanib PTK6 SSL via PTK6 1
sorafenib tosylate, valproic acid, sildenafil citrate CDKN1A SSL via CDKN1A 1
tivozanib PTK6 SSL via PTK6 1
trametinib, erlotinib MAP2K2 SSL via MAP2K2 1
trametinib, ruxolitinib MAP2K2 SSL via MAP2K2 1
trametinib, ruxolitinib TYK2 SSL via TYK2 1
trametinib, ruxolitinib, retifanlimab MAP2K2 SSL via MAP2K2 1
trametinib, ruxolitinib, retifanlimab TYK2 SSL via TYK2 1
trametinib, vinblastine MAP2K2 SSL via MAP2K2 1
valproic acid CDKN1A SSL via CDKN1A 1
valproic acid, bevacizumab, radiation therapy CDKN1A SSL via CDKN1A 1
valproic acid, simvastatin 20mg, gemcitabine 1000 mg, nab paclitaxel, cisplatin, capecitabine CDKN1A SSL via CDKN1A 1
vandetanib PTK6 SSL via PTK6 yes 1
vandetanib, 5 fluorouracil (fu), carboplatin, paclitaxel, external beam radiation therapy (rt) PTK6 SSL via PTK6 1
vandetanib, adjuvant therapy PTK6 SSL via PTK6 1
cobimetinib MAP2K2 SSL via MAP2K2 yes 0
cobimetinib fumarate MAP2K2 SSL via MAP2K2 yes 0
dasatinib LCK SSL via LCK yes 0
dasatinib SRC SSL via SRC yes 0
duvelisib PIK3CG SSL via PIK3CG yes 0
midostaurin PRKCZ SSL via PRKCZ yes 0
pazopanib LCK SSL via LCK yes 0
pazopanib hydrochloride LCK SSL via LCK yes 0
selumetinib sulfate MAP2K2 SSL via MAP2K2 yes 0
tirbanibulin SRC SSL via SRC yes 0
tofacitinib TYK2 SSL via TYK2 yes 0
tofacitinib citrate TYK2 SSL via TYK2 yes 0
trametinib MAP2K2 SSL via MAP2K2 yes 0
trametinib dimethyl sulfoxide MAP2K2 SSL via MAP2K2 yes 0
upadacitinib TYK2 SSL via TYK2 yes 0
vandetanib LCK SSL via LCK yes 0
vandetanib SRC SSL via SRC yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.